(Q53853229)

21 May 2018

title

Docetaxel: a new active agent in the therapy of metastatic breast cancer. (English)

1 reference

21 May 2018

1 reference

Fumoleau P

1

1 reference

21 May 2018

Seidman AD

2

1 reference

21 May 2018

Trudeau ME

3

1 reference

21 May 2018

Chevallier B

4

1 reference

21 May 2018

Ten Bokkel Huinink WW

5

1 reference

21 May 2018

language of work or name

English

0 references

publication date

1 December 1997

1 reference

21 May 2018

Expert Opinion on Investigational Drugs

published in

1 reference

21 May 2018

volume

6

1 reference

21 May 2018

issue

12

1 reference

21 May 2018

page(s)

1853-1865

1 reference

21 May 2018

ABC of breast diseases. Breast cancer--epidemiology, risk factors and genetics

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

ABC of breast diseases. Metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Effects of antimitotic agents on tubulin-nucleotide interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Cytoskeleton-disrupting drugs enhance effect of growth factors and hormones on initiation of DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Relationships between the structure of taxol analogs and their antimitotic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Phase I trial of Taxotere: five-day schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Phase II study of mitoxantrone for liver metastases from breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.12.1853

10.1517/13543784.6.12.1853

21 January 2018

Identifiers

DOI

1 reference

21 May 2018

1 reference

21 May 2018